No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia

Arai, Hiroyuki; Satoh‐Nakagawa, Takuma; Higuchi, Makoto; Morikawa, Yu Ichi; Miura, Masaru; Kawakami, Hisako; Seki, Hirobumi; Takase, Sadao; Sasaki, Hidetada

doi:10.1016/s0304-3940(98)00781-2

Cited by 46 publications

(25 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared with OND, t-tau levels significantly, but aspecifically, increased in AD, AD with WMC, and VD. These findings were generally expected, in agreement with the most recent literature [2 -6] (see also [39]). …”

Section: Discussionsupporting

confidence: 93%

AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis

Stefani

Bernardini

Panella

et al. 2005

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis

Stefani

Bernardini

Panella

et al. 2005

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…Increased tau levels were also found in probable VaD in concordance with some [5,10,15], but not all, studies [16][17][18]. The relation between brain ischaemia and increased CSF tau is well established [50].…”

Section: Figsupporting

confidence: 63%

“…Elevated levels of CSF tau indicating neuronal/axonal damage is also seen in stroke [10] and Creutzfeldt-Jakob disease [14]. The specificity of CSF tau in distinguishing AD from vascular dementia (VaD) has been found to be low [5,10,15], even though other studies showed normal levels of CSF tau in VaD compared with AD [11,[16][17][18]. CSF levels of Aß have been found to be decreased in AD patients compared with controls [12,[19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Cerebrospinal Fluid Phospho-Tau, Total Tau and β-Amyloid<sub>1–42</sub> in the Differentiation between Alzheimer’s Disease and Vascular Dementia

Nägga

Gottfries

Blennow

et al. 2002

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

The two most frequently examined biomarkers in the diagnosis of dementia are cerebrospinal fluid (CSF) tau and β-amyloid_1–42 (Aβ_1–42). An assay for tau phosphorylated at threonine 181 (phospho-tau) has recently been developed. We studied these three markers in patients with possible Alzheimer’s disease (AD; n = 23), probable AD (n = 50), AD with relevant cerebrovascular disease (AD with CVD; n = 14), possible vascular dementia (VaD; n = 39), probable VaD (n = 36), cognitively impaired (n = 13) and 27 neurologically healthy controls. Compared with the controls, tau levels were significantly increased in possible AD, probable AD, AD with CVD and probable VaD. Aβ_1–42 was decreased in all dementia groups compared with the controls. In contrast, phospho-tau levels were increased only in probable AD compared with the controls. From the results of the present study, it is concluded that neither measurement of phospho-tau, tau nor Aβ_1–42 in CSF can discriminate entirely between dementia and cognitively non-disturbed controls or between dementia of different aetiologies in the clinical diagnostic procedure.

show abstract

“…We rejected samples from patients diagnosed with conditions associated with AD-like CSF tau levels or featuring ongoing pathogenesis involving the limbic and isocortices (e.g. multi-infarct, vascular (17), and Lewy body (18) dementias were included; corticobasal degeneration, Pick disease, and prion diseases were excluded). Samples containing blood or other visible impurities were rejected.…”

Section: Preparation Of Csf Exosome Fractions Via Sucrose Gradient Frmentioning

confidence: 99%

Exosome-associated Tau Is Secreted in Tauopathy Models and Is Selectively Phosphorylated in Cerebrospinal Fluid in Early Alzheimer Disease

Saman

Kim

Raya

et al. 2012

Journal of Biological Chemistry

848

783

View full text Add to dashboard Cite

Background: Tau is secreted unconventionally, possibly explaining increased CSF phosphotau levels in early AD. Results: M1C cells secrete selectively phosphorylated, exosomal tau. These characteristics in early AD CSF tau suggest that CSF tau is secreted, not shed from dead neurons. Conclusion: Tau secretion occurs early and may explain lesion spreading in AD. Significance: Secretion biomarkers may become revolutionary prospective AD diagnostics.

show abstract

No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia

Cited by 46 publications

References 13 publications

AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis

AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis

Cerebrospinal Fluid Phospho-Tau, Total Tau and β-Amyloid<sub>1–42</sub> in the Differentiation between Alzheimer’s Disease and Vascular Dementia

Exosome-associated Tau Is Secreted in Tauopathy Models and Is Selectively Phosphorylated in Cerebrospinal Fluid in Early Alzheimer Disease

Contact Info

Product

Resources

About